ArticleJournal of Cancer2017
PET of HER2 Expression with a Novel
Article in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring.The oncologist · 2025Trial
- Article
- Ternary classification prediction and heterogeneity quantification for HER2-Zero, -low, and -positive in breast cancer using HER2-targeted PET/CT imaging.European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluation of chicken chorioallantoic membrane model for tumor imaging and drug development: Promising findings.Animal models and experimental medicine · 2025Article
- Novel Molecular Classification of Breast Cancer with PET Imaging.Medicina (Kaunas, Lithuania) · 2024Review
- Preclinical research progress in HER2-targeted small-molecule probes for breast cancer.Radiologie (Heidelberg, Germany) · 2024Review
- The diagnostic value ofFrontiers in medicine · 2024Article
- Druggability of Targets for Diagnostic Radiopharmaceuticals.ACS pharmacology & translational science · 2023Review
- Application of a NovelFrontiers in oncology · 2022Article
- Pre-Clinical Study of the [Frontiers in medicine · 2022Article
- Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer.International journal of molecular sciences · 2021Article
- The aluminium-[EJNMMI radiopharmacy and chemistry · 2021Review
- PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.International journal of molecular sciences · 2021Review
- Radiolabeled Peptides and Antibodies in Medicine.Bioconjugate chemistry · 2021Review
- Impact ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Synthesis of a novelEJNMMI research · 2020Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Affibody Molecules as Targeting Vectors for PET Imaging.Cancers · 2020Review
- Visualization of gene therapy with a liver cancer-targeted adeno-associated virus 3 vector.Journal of Cancer · 2020Article
- PET imaging of aThe British journal of radiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.